GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2011

SMA Foundation and Rules-Based Medicine Report Progress with SMA Biomarker Panel Development

SMA Foundation and Rules-Based Medicine Report Progress with SMA Biomarker Panel Development

Organizations plan to develop panel of biomarker assays for use in clinical trials of SMA therapeutic candidates.[]

  • The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine report reaching the final milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) platform. The collaboration has focused on the discovery and validation of plasma protein biomarkers identified previously by the Biomarkers for SMA (BforSMA) clinical study, which was sponsored by the SMA Foundation and carried out by BG Medicine. The BforSMA study plasma samples were provided to RBM for processing on its DiscoveryMAP™ platform, together with an additional set of 70 biomarker assays.

    The Foundation and RBM are now continuing to analyze candidate biomarkers identified through their ongoing partnership, with the aim of creating a specific panel of biomarker assays for use in clinical trials evaluating new therapeutic candidates for SMA. “Our MAP technology has been effective as part of many therapeutic development programs and for identifying biomarker patterns linked to complex diseases,” comments Craig Benson, CEO at RBM. “The confirmation and validation of biomarker patterns on our platform and the availability of testing services through our CLIA-certified lab will accelerate the development of new treatments for SMA.”

    RBM provides comprehensive protein biomarker products and services based on its MAP technology platform. The firm’s flagship product, VeriPsych™, was launched commercially in October 2010 as a 51-biomarker test designed to compare a suspected schizophrenia patient’s biomarker profile to that of confirmed schizophrenic patients as an aid to diagnosis.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »